host picture

Is the little pink pill worth celebrating?

Some are calling it a game changer, a giant step forward for women. Others caution that the newly FDA approved libido enhancing drug for women, Addyi, imposes a problem on women that doesn't exist. Both sides agree, with 28 drugs on the market for men and one for women, something seems unfair.


Our guests are both clinical psychologists who were involved in the trials for flibanserin but came to different conclusions. They were paid by the pharmaceutical company for their work.


Sheryl Kingsberg is Chief of Behavioral Medicine in the Department of Obstetrics and Gynecology at University Hospitals Case Medical Centre; and a professor of reproductive biology and psychiatry at Case Western Reserve University in Cleveland. She worked closely with the company that developed Addyi. READ her op-ed piece on why it is a turning point.


Caroline Pukall is a psychology professor at Queens University in Kingston where she is Director of Sex Therapy Service in the Psychology Clinic and Director of the SexLab.


Looking for a podcast? CLICK HERE  

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Submission Policy

Note: The CBC does not necessarily endorse any of the views posted. By submitting your comments, you acknowledge that CBC has the right to reproduce, broadcast and publicize those comments or any part thereof in any manner whatsoever. Please note that comments are moderated and published according to our submission guidelines.